Recent findings concerning thiazolidinediones in the treatment of diabetes

Bibliography

• CHANG AY, WYSE BM, GILCHRIST BJ, PETERSON T, DIANI AR: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/ob mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes (1983) 32:830-838.
   Google Scholar
• ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:645-650.
   Google Scholar
• BERGER J, MOLLER DE: Mechanism of action of PPARs. Ann. Rev. Med. (2002) 53:409-435.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor γ (PPAR-γ). J. Biol. Chem. (1995) 270:12953-12956.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, COBB JE, COWAN DJ et al.: The structure–activity relationship between peroxisome proliferators-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665-668.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, OLEFSKY JM, NYCE MR, CONSIDINE RV, CARO JF: Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes (1996) 45:1276-1278.
   PubMedGoogle Scholar
• GHAZZI M, PEREZ J, ANTONUCCI T et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes (1997) 46:433-439.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661-1669.
   PubMed Web of Science ®Google Scholar
• DE FRONZO RA, JACOT E, JEQUIER E et al.: The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes (1981) 30:1000-1007.
   PubMed Web of Science ®Google Scholar
• PANIGRAHY D, SHEN LQ, KIERAN MW, KAIPAINEN A: Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Invest. Drugs (2003) 12:1925-1937.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, HU E, GRAVES RA et al.: mPPAR γ 2: tissue-specific regulator of an adipocytes enhancer. Genes Dev. (1994) 8:1224-1234.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, LAMBERT MH, KLIEWER SA: Peroxisome proliferators-activated receptor γ and metabolic disease. Ann. Rev. Biochem. (2001) 70:341-367.
   PubMed Web of Science ®Google Scholar
• BODEN G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes (1997) 46:3-10.
   PubMed Web of Science ®Google Scholar
• BODEN G, LAAKSO M: Lipids and glucose in Type 2 diabetes. What is the cause and effect? Diabetes Care (2004) 27:2253-2259.
   PubMed Web of Science ®Google Scholar
• BODEN G, HOMKO C, MOZZOLI M, SHOWE LC, NICHOLS C, CHEUNG P: Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue in diabetic patients. Diabetes (2005) 54:880-885.
   PubMed Web of Science ®Google Scholar
• BODEN G, CHEUNG P, MOZZOLI M, FRIED SK: Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with Type 2 diabetes. Metabolism (2003) 52:753-759.
   PubMed Web of Science ®Google Scholar
• ITANI SI, RUDERMAN NB, SCHMIEDER F et al.: Lipid induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C and IκB-α. Diabetes (2002) 51:2005-2011.
   PubMed Web of Science ®Google Scholar
• BODEN G, SHE P, MOZZOLI M et al.: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes (2005) 54:3458-3465.
   PubMed Web of Science ®Google Scholar
• YU C, CHEN Y, CLINE GW et al.: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. (2002) 277:50230-50236.
   PubMed Web of Science ®Google Scholar
• KIM JK, KIM YJ, FILLMORE JJ et al.: Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. (2001) 108:437-446.
   PubMed Web of Science ®Google Scholar
• MAEDA N, TAKAHASHI M, FUNAHASHI T et al.: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 50:2094-2099.
   PubMed Web of Science ®Google Scholar
• YANG WS, JENG CY, WU TJ et al.: Synthetic peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in Type 2 diabetic patients. Diabetes Care (2002) 25:376-380.
   PubMed Web of Science ®Google Scholar
• HOTTA K, FUNAHASHI T, ARITA Y et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Aterioscler. Thromb. Vasc. Biol. (2002) 20:1595-1599.
   Web of Science ®Google Scholar
• YAMAUCHI T, KAMON J, WAKI H et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. (2001) 7:941-946.
   PubMed Web of Science ®Google Scholar
• KLETZIEN RE, CLARKE SD, ULRICH RG: Enhancement of adipocytes differentiation by an insulin-sensitizing agent. Mol. Pharmacol. (1992) 41:393-398.
   Google Scholar
• TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAR-γ 2, a lipid activated transcription factor. Cell (1994) 79:1147-1156.
   PubMed Web of Science ®Google Scholar
• DE SOUZA CJ, ECKHARDT M, GAGEN K et al.: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes (2001) 50:1863-1871.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI Y, MAHANKALI A, MATSUDA M et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2002) 87:2784-2791.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes (2002) 51:2796-2803.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC, HAMMAN RF, EDELSTEIN SL et al.: Diabetes Prevention Program Research Group: prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 54:1150-1156.
   PubMed Web of Science ®Google Scholar
• GALE EA: Lessons from the glitazones: a story of drug development. Lancet (2001) 357:1870-1875.
   PubMed Web of Science ®Google Scholar
• NATHAN DM: Initial management of glycemia in Type 2 diabetes mellitus. N. Engl. J. Med. (2002) 347:1342-1349.
   PubMed Web of Science ®Google Scholar
• DE FRONZO RA, GOODMAN AM: Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. (1995) 333:541-549.
   PubMed Web of Science ®Google Scholar
• ARONOFF S, ROSENBLATT S, BRAITHWAITE S, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care (2000) 23:1605-1611.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, DOLE JF, PATWARDHAN R, RAPPAPORT EB, FREED MI: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab (2001) 86:280-288.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO J, KIMURA H, MORIYAMA S et al.: Activation of human peroxisome proliferators-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. (2000) 278:704-711.
   PubMed Web of Science ®Google Scholar
• GROSSMAN SL, LESSEM J: Mechanisms and clinical effects of thiazolidinediones. Expert Opin. Investig. Drugs (1997) 6:1025-1040.
   PubMedGoogle Scholar
• LEBOVITZ HE, KREIDER M, FREED MI: Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care (2002) 25:815-821.
   PubMed Web of Science ®Google Scholar
• MUDALIAR S, CHANG AR, HENRY RR: Thiazolidinediones, peripheral edema, and Type 2 diabetes:incidence, pathophysiology, and clinical implications. Endocr. Pract. (2003) 9:406-416.
   PubMedGoogle Scholar
• PAGE RL II, GOZANSKY WS, RUSCIN JM: Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy (2003) 23:945-954.
   PubMed Web of Science ®Google Scholar
• KING KA, LEVI VE: Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinediones. Am. J. Health Sys. Pharm. (2004) 61:390-393.
   PubMed Web of Science ®Google Scholar
• ZHANG H, ZHANG A, KOHAN DE, NELSON RD, GONZALEZ FJ, YANG T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc. Natl. Am. Soc. (2005) 102:9406-9411.
   PubMed Web of Science ®Google Scholar
• GUAN Y, HAO C, CHA DR et al.: Thiazolidinediones expand body fluid volume through PPARγ stimulation of EnaC-mediated renal salt absorption. Nat. Med. (2005) 11:861-866.
   Google Scholar
• UK PROSPECTIVE DIABETESSTUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
   PubMed Web of Science ®Google Scholar
• YIP J, FACCHINI FS, REAVEN GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. (1998) 83:2773-2776.
   PubMed Web of Science ®Google Scholar
• SMILEY T, OH P, SHANE LG: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systematic review. Can. J. Cardiol. (2001) 17:797-805.
   PubMed Web of Science ®Google Scholar
• CLOUGH MH, SCHNEIDER DJ, SOBEL BE, WHITE MF, WADSWORTH MP, TAATJES DJ: Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. J. Histochem. Cytochem. (2005) 53:603-610.
   PubMed Web of Science ®Google Scholar
• LAW RE, GOETZE S, XI X-P et al.: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation (2000) 101:1311-1318.
   PubMed Web of Science ®Google Scholar
• RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79-82.
   PubMed Web of Science ®Google Scholar
• MARX N, SUKHOVA G, MURPHY C, LIBBY P, PLUTZKY J: Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am. J. Pathol. (1998) 153:17-23.
   PubMed Web of Science ®Google Scholar
• MASOUDI FA, INZUCCHI SE, WANG Y, HAVRANEK EP, FOODY JM, KRUMHOLZ HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. Circulation (2005) 111:583-590.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DA et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (PROspective Pioglitazone Clinical Trial In Macrovascular Events): a randomized controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• STAELS B, FRUCHART J-C: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 54:2460-2470.
   PubMed Web of Science ®Google Scholar
• ANGULO P: Nonalcoholic fatty liver disease. N. Engl. J. Med. (2002) 346:1221-1231.
   PubMed Web of Science ®Google Scholar
• BELLENTANI S, SACCOCCIO G, MASUTTI F et al.: Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann. Intern. Med. (2000) 132:112-117.
   PubMed Web of Science ®Google Scholar
• NOMURA H, KASHIQAGI S, HAYASHI J, KAJIYAMA W, TANI S, GOTO M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J. Med. (1988) 27:142-149.
   PubMedGoogle Scholar
• LUYCKZ FH, DESAIVE C, THIRY A et al.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord. (1998) 22:222-226.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JF, PORIES WJ, CARO JF: Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol. Ann. (1989) 24:275-302.
   Google Scholar
• CLARK JM, BRANCATI FL, DIEHL AME: Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population. Gastroenterology (2001) 120:A-65 (Supplement).
   Google Scholar
• MARCHESINI G, BRIZI M, MORSELLI-LABATE AM et al.: Association of non-alcoholic fatty liver disease with insulin resistance. Am. J. Med. (1999) 107:450-455.
   PubMed Web of Science ®Google Scholar
• CAREY DG, COWIN GJ, GALLOWAY GJ et al.: Effect of rosiglitazone on insulin sensitivity and body composition in Type 2 diabetic patients. Obes. Res. (2002) 10:1008-1015.
   PubMedGoogle Scholar
• MAYERSON AB, HUNDAL RS, DUFOUR S et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes (2002) 51:797-802.
   Google Scholar
• BAJAJ M, SURAAMORNKUL S, PRATIPANAWATR T et al.: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with Type 2 diabetes. Diabetes (2003) 52:1364-1370.
   Google Scholar
• TIIKKAINEN M, HAKKINEN A-M, KORSHENINNIKOVA E, NYMAN T, MAKIMATTILA S, YKI-HARVINEN H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with Type 2 diabetes. Diabetes (2004) 53:2169-2176.
   Google Scholar
• NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, OLIVER D, BACON BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology (2003) 38:1008-1017.
   PubMed Web of Science ®Google Scholar
• KNOCHENHAUER ES, KEY TJ, KAHSAR-MILLER M, WAGGONER W, BOOTS LR, AZZIZ R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the south-eastern United States: a prospective study. J. Clin. Endocrinol. Metab. (1998) 83:3078-3082.
   PubMed Web of Science ®Google Scholar
• IUORNO MJ, NESTLER JE: Insulin-lowering drugs in polycystic ovary syndrome. Obstet. Gynecol. Clin. North Am. (2001) 28:153-164.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab (1997) 82:2108-2116.
   PubMed Web of Science ®Google Scholar
• AZZIZ R, EHRMANN D, LEGRO RS et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. (2001) 86:1626-1632.
   PubMed Web of Science ®Google Scholar
• PARADISI G, STEINBERG HO, SHEPARD MK, HOOK G, BARON AD: Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2003) 88:576-580.
   PubMed Web of Science ®Google Scholar
• TARKUN I, CETINARSLAN B, TUREMEN E, SAHIN T, CANTURK Z, KOMSUOGLU B: Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur. J. Endocrinol. (2005) 153:115-121.
   PubMed Web of Science ®Google Scholar
• SETO-YOUNG D, PALIOU M, SCHLOSSER J et al.: Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects of steroidogenesis and insulin-like growth factor binding protein-1 production. J. Clin. Endocrinol. Metab. (2005) 90:6099-6105.
   PubMed Web of Science ®Google Scholar
• ARIOGLU E, DUNCAN-MORIN J, SEBRING N et al.: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. (2000) 133:263-274.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
   PubMed Web of Science ®Google Scholar
• HADIGAN C, YAWETZ S, THOMAS A, HAVERS F, SAX PE, GRINSPOON S: Metabolic effects of rosiglitazone in HIV lipodystrophy. A randomized controlled trial. Ann. Intern. Med. (2004) 140:786-794.
   PubMed Web of Science ®Google Scholar
• TOMAZIC J, KARNER P, VIDMAR L, MATICIC M, HARMA PM, JANEZ A: Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatoven APA (2005) 14:99-105.
   Google Scholar
• SUTINEN J, HAKKINEN A-M, WESTERBACKA J et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study. Antivir. Ther. (2003) 8:199-207.
   PubMed Web of Science ®Google Scholar
• LJUNG B, BAMBERG K, DAHLLOF B et al.: AZ242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. (2002) 43:1855-1863.
   PubMed Web of Science ®Google Scholar
• ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptorα/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083-1087.
   PubMed Web of Science ®Google Scholar
• MARX N, MACKMAN N, SCHONBECK U et al.: PPARα activators inhibit tissue factor expression and activity in human monocytes. Circulation (2001) 103:213-219.
   PubMed Web of Science ®Google Scholar
• NEVE BP, CORSEAUX D, CHINETTI G et al.: PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation (2001) 103:207-212.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K, TOPOL EJ: Effect muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. J. Am. Med. Assoc. (2005) 294:1-6.
   Google Scholar